Navigation Links
FDA Panel Appears Skeptical Over Key Avandia Data
Date:7/13/2010

dia for physicians fighting diabetes," said Dr. Ellen Strahlman, Glaxo's chief medical officer, in a statement released at the time. "We believe that the results showed that Avandia is safe."

On Friday, the company, in a prepared statement, said, "The RECORD study was conducted according to good clinical practices and the data are reliable. . . RECORD demonstrated that Avandia was not associated with an overall increase in cardiovascular hospitalization or cardiovascular death compared to metformin and sulfonylureas."

According to the Times, Marciniak was on hand at Tuesday's hearings and reiterated his doubts about RECORD. He pointed to the case of one participant in the trial whose heart attack was excised from his medical record by the doctor in charge of those materials.

"I think this type of handling of events is completely unacceptable, Marciniak told those at the hearing.

But the researcher in charge of RECORD defended the trial's integrity. Dr. Philip Home, professor of diabetes medicine at Newcastle University, to panel members that contrary to the allegations in an editorial published in last week's New England Journal of Medicine, the trial's independent safety committee "was not compromised by GSK in 2007."

Also on Tuesday, groups including the American Diabetes Association, the American Association of Clinical Endocrinologists and The Endocrine Society issued a joint statement advising patients who are using Avandia to hold steady for now.

"Patients should continue taking all currently prescribed medications unless instructed otherwise by their health care provider," the experts said. "Stopping diabetes medications can result in higher levels of blood glucose that may cause serious short-term health problems and could increase the risk of diabetes-related complications in the long term."

They added that "until further clarification is provided by the FDA, the decision whether or not to use a
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. NJIT professor heads panel studying sudden car acceleration
2. FDA Panel Votes Against Approval of Female Viagra
3. FDA Panel Weighs OK of Female Viagra
4. FDA Panel Backs New Morning After Pill
5. FDA Panel to Vote on New Morning After Pill
6. U.S. Panel Upholds Ban on Gay Men as Blood Donors
7. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
8. DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It
9. ANY LAB TEST NOW Launches New Infectious Disease Panels - Affordable Panels Test for H1N1, Staph, E. coli and Other Infectious Diseases
10. PSA-TEC to Present State of the Industry Panel Discussion
11. Panel recommends standardizing prescription container labeling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Appears Skeptical Over Key Avandia Data
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Nov. 28 GAB Robins is pleased to,announce that ... Adjusting,Sales for North American Operations. In this position, Ms. ... and will be responsible for,increasing business development opportunities for ... been with GAB Robins for seven years. Most recently, ...
... Nov. 28 In recognition of,National ... Inc., (http://www.HealthCentral.com ) today has launched ... informs online users about acne,aging skin, ... reliable medical information and a,community forum ...
... N.J., Nov. 28 RadPharm, Inc., a leading,provider ... announced,the completion of a $10 million Series B ... Ampersand Ventures, Adams Street,Partners and Tang Capital Management ... wealth of expertise in medical imaging and clinical,research, ...
... HUBBARD, Ohio, Nov. 28 NanoLogix, Inc. ... that the company has,submitted international patent applications ... China, India, Brazil, and the,EU (European Union). ... anticipated,global roll-out of the company,s BioNanoChannel(TM) rapid,bacteria/microorganism ...
... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin ... industry engaged in the development, manufacture and,distribution ... care products in China, today announced that ... Asia institutional investor conference on,December 5, 2007 ...
... Patient Implanted in San Antonio, TX -, ORANGEBURG, ... began patient enrollment in a national diabetes clinical,trial of ... with type 2 diabetes who are overweight. The study ... United States., The 300-patient trial will evaluate the ...
Cached Medicine News:Health News:The HealthCentral Network Adds Skin Care Site to Its Web Properties 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology 2Health News:China Yingxia to Present at the ICR XChange Asia Institutional Investor Conference 2Health News:MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 2
(Date:8/1/2014)... 1, 2014 In the latest call for ... dysfunction, more than 60 doctors and leading medical experts ... questioning the Food and Drug Administration,s (FDA) decision to ... of male sexual dysfunction compared with ZERO for women,s ... act for women by approving the first-ever drug to ...
(Date:8/1/2014)... 2014 In the latest call for gender ... more than 60 doctors and leading medical experts from ... the Food and Drug Administration,s (FDA) decision to approve ... male sexual dysfunction compared with ZERO for women,s most ... for women by approving the first-ever drug to treat ...
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it ... This designation recognizes Aspire for delivering outstanding customer service to ... . "Achieving exceptional results for our customers is ... President and CEO of Aspire. "We are pleased Cisco has ... award and are proud to be part of the Cisco ...
Breaking Medicine Technology:60+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
... May 3, 2012 /PRNewswire-Asia/ -- Johnson & ... has acquired Guangzhou Bioseal Biotechnology Co., Ltd. ... in the design, development and commercialization of ... bleeding during surgery. The acquisition was completed ...
... Cochlear Americas , the world,s leading implantable hearing ... smartphone support application for Nucleus® Cochlear Implant recipients. ... App as part of Cochlear,s mobile support initiative, ... and wherever they need it. (Photo: ...
Cached Medicine Technology:Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2Cochlear™ Americas Adds the Nucleus® Support App to its Mobile Service Offerings 2
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: